Gossamer Bio, Inc.
GOSSNasdaq
$0.17
↓ -0.2%Jul 17 close · end-of-day
Price
1Y↓ -89.8%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$39.8M
Enterprise Value
-$59.4M
P/E
—
P/S
0.7
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
-427.6%
Dividend Yield
—
Revenue (TTM)
$55.5M
Net Income (TTM)
-$180.4M
Free Cash Flow (TTM)
-$170.3M
Gross Margin
—
Operating Margin
-321.9%
Net Margin
-324.8%
ROE
111.7%
ROIC
—
Debt / Equity
—
Net Cash
$99.2M
Return 1Y
-90.0%
Company profile
Gossamer Bio, Inc. focuses on discovering, acquiring, developing, and commercializing therapeutics in immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor. GB5121, an oral, irreversible, covalent, small. molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central. central central nervous system lymphoma.
- CEO
- Faheem Hasnain
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 180
- Headquarters
- California
- Website
- gossamerbio.com
Management & directors
- Aranda RichardChief Medical Officer
- Christian WaageEVP, Tech Ops and Admin
- Giraudo BryanCOO/CFO
- Hasnain FaheemPresident & CEO
- Peterson CarynEVP, Regulatory Affairs
- Smith Robert Paul JrChief Commercial Officer
Roles derived from SEC Form 4 filings.
Earnings
GOSS Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$17.0M↑ +71.5%
Diluted EPS-$0.20↑ +25.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | $0.00 | $0.00 | $114.7M | $48.5M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$234.0M | -$216.1M | -$218.6M | -$183.8M | -$59.9M | -$170.7M |
| Net income | -$243.4M | -$234.0M | -$229.4M | -$179.8M | -$56.5M | -$170.4M |
| Diluted EPS | -$3.55 | -$3.13 | -$2.71 | -$1.18 | -$0.25 | -$0.75 |
| Operating cash flow | -$176.4M | -$188.9M | -$187.0M | -$159.2M | -$3.5M | -$171.3M |
| Free cash flow | -$177.9M | -$190.4M | -$187.4M | -$159.2M | -$3.5M | -$171.3M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | -52.2% | -352.2% |
| Net margin | — | — | — | — | -49.3% | -351.5% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $95.8M | $9.5M | $9.4M | $9.9M | $11.5M | $13.3M | $13.8M | $17.0M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $52.1M | -$33.9M | -$36.1M | -$36.8M | -$38.8M | -$49.1M | -$46.0M | -$44.9M |
| Net income | $49.2M | -$30.8M | -$33.0M | -$36.6M | -$38.3M | -$48.2M | -$47.2M | -$46.7M |
| Diluted EPS | $0.22 | -$0.14 | -$0.14 | -$0.16 | -$0.17 | -$0.21 | -$0.21 | -$0.20 |
| Operating cash flow | $116.3M | -$32.0M | -$35.5M | -$39.7M | -$47.1M | -$36.2M | -$48.3M | -$38.7M |
| Free cash flow | $116.3M | -$32.0M | -$35.5M | -$39.8M | -$47.1M | -$36.2M | -$48.3M | -$38.7M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | 54.3% | -357.8% | -385.2% | -372.2% | -337.4% | -369.4% | -333.6% | -264.6% |
| Net margin | 51.4% | -324.9% | -352.2% | -370.5% | -333.1% | -362.7% | -342.3% | -275.2% |
Company news
Jun 18, 2026
Jun 17, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-01-02 | Hasnain Faheem· President & CEO | Award | 280,000 | $0.00 | $0.00 | filing |
| 2026-01-02 | Giraudo Bryan· COO/CFO | Award | 115,750 | $0.00 | $0.00 | filing |
| 2026-01-02 | Smith Robert Paul JR· Chief Commercial Officer | Award | 93,750 | $0.00 | $0.00 | filing |
| 2026-01-02 | Aranda Richard· Chief Medical Officer | Award | 93,750 | $0.00 | $0.00 | filing |
| 2026-01-02 | Peterson Caryn· EVP, Regulatory Affairs | Award | 84,500 | $0.00 | $0.00 | filing |
| 2026-01-02 | Christian Waage· EVP, Tech Ops and Admin | Award | 84,500 | $0.00 | $0.00 | filing |
| 2025-10-01 | Smith Robert Paul JR· Chief Commercial Officer | Award | 162,500 | $0.00 | $0.00 | filing |
| 2025-10-01 | Christian Waage· EVP, Tech Ops and Admin | Award | 125,000 | $0.00 | $0.00 | filing |
| 2025-10-01 | Giraudo Bryan· COO/CFO | Award | 181,250 | $0.00 | $0.00 | filing |
| 2025-10-01 | Aranda Richard· Chief Medical Officer | Award | 162,500 | $0.00 | $0.00 | filing |
| 2025-10-01 | Hasnain Faheem· President & CEO | Award | 437,500 | $0.00 | $0.00 | filing |
| 2025-10-01 | Peterson Caryn· EVP, Regulatory Affairs | Award | 125,000 | $0.00 | $0.00 | filing |
| 2025-08-19 | Milligan Sandra | Buy | 26,050 | $1.92 | $50,016.00 | filing |
Latest 13 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.